Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results

Fig. 4

Treatment outcome based on HER2/CEP17 ratio and HER2 IHC. A Progression-free survival according to HER2/CEP17 ratio in HER2 IHC 1+/2+ (n = 23) and B HER2 IHC 3+ (n = 55). C Overall survival according to HER2/CEP17 ratio in HER2 IHC 1+/2+ (n = 23) and D HER2 IHC 3+ (n = 55)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us